$249 Million is the total value of TCG Crossover Management, LLC's 20 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
GERN | New | Geron Corporation | $19,429,000 | – | 14,285,715 | +100.0% | 7.80% | – |
New | Tango Therapeutics, Inc. | $9,509,000 | – | 1,254,500 | +100.0% | 3.82% | – | |
KURA | New | Kura Oncology, Inc. | $8,143,000 | – | 506,423 | +100.0% | 3.27% | – |
New | Pardes Biosciences, Inc. | $1,654,000 | – | 229,100 | +100.0% | 0.66% | – | |
ANAB | New | AnaptysBio, Inc. | $1,448,000 | – | 58,515 | +100.0% | 0.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
MERUS N.V. | 8 | Q3 2023 | 3.4% |
IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
Geron Corporation | 7 | Q3 2023 | 12.4% |
ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
SC 13G | 2022-08-19 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-18 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.